--- Chain 4 for Question 102 ---
Status: COMPLETED
Is Active Flag: True
Finish Reason: stop
Reasoning Complete Flag: True
Error: None
Prompt Tokens: 439
Completion Tokens: 8150
Completed Thoughts: 10
Accumulated Pruned Count: 7
Final Mean Pairwise Similarity: 0.5769
Final Internal Similarity: 0.0577
Final Processed Boundaries: [0, 1518, 1872, 2238, 2511, 2622, 2844, 3348, 3951, 4577]

--- Full Content ---
Okay, so I've got this biology question here, and I'm trying to figure it out step by step. Let me read it again and digest the details.

The question is about a ligand-receptor pair expressed in neural crest cells, and we're looking into their developmental fate. So, the setup involves some molecular biology techniques, like using a bicistronic vector with loxP sites and IRES elements. The experiment involves creating a transgenic mouse model and then using Cre recombinase to see if the constructs are properly expressed.

Alright, the problem says that when they breed the mouse model homozygous for the construct in a wild-type background and cross it with SOX10-Cre hemizygous mice, they don't observe a green signal under the confocal microscope. Since the receptor is fused to eGFP, the absence of green suggests that the receptor-eGFP isn't being expressed or isn't functional.

Let me break down the vector structure. The vector is bicistronic, meaning it has two ORFs (ligand and receptor) under different promoters or regulatory elements. The ligand is at the 5' position, fused to mCherry, and the receptor is at the 3' position, fused to eGFP. 

So, the ligand is under the CBA promoter. Upstream of the receptor is the IRES element. IRES elements allow for internal ribosome entry sites, which can drive the translation of the downstream ORF without the need for a separate promoter, right? So that would mean the receptor is under the control of the same promoter as the ligand, but after an IRES.

Wait, the vector has a loxP-stop-loxP cassette between the ligand ORF and mCherry. And between the receptor and eGFP is a lox2272-stop-lox2272 cassette. So, without Cre, these stop cassettes would prevent expression of the mCherry and eGFP. But when Cre is present, it would recombine the lox sites, removing the stop cassettes and allowing expression.

Wait, loxP and lox2272 are different lox sites; they're recognized by different Cre variants. LoxP is the standard site, and lox2272 is a variant that is used with Cre-ER or other modified Cre systems because they have different recombination specificities. So if you use standard Cre, it should recombine loxP sites but not lox2272. Or is it the other way around?

Wait, no, standard Cre binds both loxP and lox2272 sites, but lox2272 is a mutated version where Cre can only recombine when in a certain configuration, like with FLP recombinase. Hmm, I'm a bit fuzzy on that. Alternatively, maybe the standard Cre can't recombine lox2272. Wait, I think that lox2272 is a "floxed" site that requires a different Cre, but I might be mixing things up.

Wait, another thought: loxP is the original site, and Cre can recombine them. lox2272 is a variant that has different recombination properties; perhaps Cre cannot efficiently recombine them unless in a particular context. Alternatively, maybe the lox2272 requires a different Cre variant, like Cre-ERT2, which is often used for tissue-specific expression when induced by tamoxifen.

But in this case, the Cre used is SOX10-Cre. SOX10 is a transcription factor expressed in neural crest cells, so the Cre is probably under the control of SOX10 regulatory elements, meaning it's active in neural crest-derived cells. So when the mouse is crossed with SOX10-Cre, the Cre would recombine the lox sites in the neural crest cells.

Wait, but the vector has two different lox sites: the ligand's stop cassette is flanked by loxP, and the receptor's stop is flanked by lox2272. So with SOX10-Cre, which can only recombine loxP sites, perhaps. Or maybe the Cre can recombine both? I'm a bit confused here.

So the idea is that the Cre would cause the stop cassettes to be removed, allowing the expression of the respective fluorescent proteins. The ligand is under the CBA promoter, which is a strong promoter, and the receptor is after the IRES, so it should be expressed in the same transcript as the ligand but translated separately.

Wait, but wait. The vector is a bicistronic vector. So the first ORF (ligand) is under the CBA promoter, then there's a stop cassette for loxP. The second ORF (receptor) is after the IRES, which is a way to have two coding regions in one transcript. So in the absence of Cre, the stop cassette for mCherry would prevent its expression. Similarly, the stop cassette for eGFP would prevent its expression.

When Cre is introduced, it should excise the loxP stop cassette after the ligand, allowing mCherry to be expressed. Similarly, it should excise the lox2272 stop cassette after the receptor, allowing eGFP to be expressed. Wait, but if the Cre can't recombine the lox2272 sites, then the eGFP stop cassette wouldn't be cut, so the eGFP won't be expressed.

Wait, the question says that the mouse is crossed with SOX10-Cre. The Cre is under the control of SOX10, so it's expressed in neural crest-derived cells. So in the offspring, the Cre should be active in neural crest cells, leading to the excision of the stop cassettes.

But the result is that they don't see any green signal. So the eGFP isn't expressed.

Looking at the options:

Option A: ligand and receptor are in a paracrine relationship. Paracrine means they act on nearby cells. But the question is about expression of the receptor-eGFP. Not sure how this affects expression.

Option B: the receptor-eGFP construct is stuck in the Golgi. If this were the case, perhaps the GFP wouldn't be on the cell surface, but the Western blot would show the protein. But the Western blot is done on total proteins, and the signal is proportional to actin loading, which suggests that the proteins are being expressed. Wait, but the question says that the Western blot was done after plasmid transfection in primary astrocytes. So that's a separate experiment. The main experiment is in the mouse.

If the eGFP is not expressed in the mouse, then the construct isn't working. So perhaps the eGFP isn't being expressed because the stop cassette isn't excised.

Wait, but when the mouse is made homozygous for the construct, the Cre is introduced by the SOX10-Cre. So the Cre should excise the lox sites. But maybe the Cre isn't active, or the lox sites are not compatible.

Wait, but the vector uses loxP and lox2272. The Cre used is SOX10-Cre. If SOX10-Cre can only recombine loxP sites, then the lox2272 sites wouldn't be cut. So the stop cassette after the receptor wouldn't be removed, so the eGFP wouldn't be expressed.

Because the lox2272 cassette isn't recombined. Let me think.

In the vector, the ligand is after CBA promoter, followed by a stop cassette with loxP. The receptor comes after IRES, followed by a stop cassette with lox2272. So when Cre is introduced, which Cre can recombine both loxP and lox2272?

Wait, no, I think that standard Cre can recombine loxP sites but not lox2272. Alternatively, lox2272 is a variant that requires a different Cre, like the one used in FLP-FRT systems.

Wait, no, FLP uses FRT sites, which are different. LoxP and lox2272 are Cre sites. I think that lox2272 is a variant where Cre can recombine them only when they are in a certain configuration, or maybe they are the same as loxP sites. Or perhaps the Cre used here doesn't recognize the lox2272 sites.

If the Cre can't recombine the lox2272 sites, then the stop cassette after the receptor (the eGFP) isn't removed, so the eGFP isn't expressed. Hence, no green signal.

So in the mouse, the Cre would recombine the loxP sites but not the lox2272 sites, leading to excision of the loxP stop cassette but not the lox2272 stop cassette. Thus, the mCherry would be expressed, but the eGFP would not. But in the question, they're looking for eGFP, which isn't expressed, hence no green.

So the reason for the lack of green is that the Cre can't recombine the lox2272 sites, so the stop isn't removed. Therefore, the eGFP isn't expressed.

Looking at the options, option D says the receptor and eGFP are not in the frame. Wait, that would be a problem if the reading frame is wrong, leading to a nonfunctional or truncated protein, but the question is about whether the eGFP is expressed at all, not whether the protein is functional.

Option C says the enhancer for ligand and receptor expression is missing. But the ligand is under the CBA promoter, which is a strong promoter, and the receptor is after an IRES. So the enhancer shouldn't be the issue, unless the CBA promoter doesn't drive expression in the cells of interest.

Alternatively, perhaps the issue is the IRES. IRES elements require specific conditions for efficient translation, like stress conditions. Maybe in the cells, the IRES isn't active, so the receptor isn't expressed. But the problem is about the eGFP not being expressed, which is downstream of the IRES.

Wait, but in the vector setup, the ligand is in frame, but the receptor is after the IRES, which might require proper ribosome positioning. However, the presence of the stop cassette upstream of the eGFP would prevent its expression unless Cre removes it.

So if the Cre can't remove the stop cassette, then eGFP isn't expressed.

Which option aligns with that? Let me look again.

Option D: the receptor and the eGFP are not in the frame. That would cause a frameshift, leading to a nonfunctional protein, but I don't think that's the issue here because the problem is about the absence of the fluorescent signal, not the functionality.

Option C says the enhancer for the ligand and receptor expression is missing. If the enhancer were missing, then both might not be expressed, but the ligand is under a strong promoter (CBA), so maybe the problem is with the enhancer for the receptor. But the IRES is a translational element, not dependent on enhancers. Hmm.

Option B: the receptor-eGFP construct is stuck in the Golgi. That's a trafficking issue. If the protein isn't getting to the cell surface, then the eGFP wouldn't be visible. But if that were the case, the Western blot should still show the protein, but perhaps not on the cell surface. However, the question mentions that the Western blot was done with total proteins, which would detect the receptor regardless of its localization. So if the protein is made but not trafficked, the Western would still show a band. But the question's result is about the fluorescence, not the Western. Wait, but the initial Western was to check expression after plasmid transfection, which was successful. But the mouse experiment's result is about the eGFP not being expressed.

Wait, in the mouse model, they're using the Cre to delete the stop cassettes. If the Cre doesn't delete the lox2272 site, then the eGFP is not expressed. So the reason is that the Cre cannot recombine the lox2272 sites.

Wait, but SOX10-Cre is a standard Cre, and it should be able to recombine loxP sites but not lox2272 sites. So the lox2272 sites are not recombined, so the eGFP isn't expressed.

Looking back at the options, is any option suggesting that the stop cassette isn't removed because of the lox site?

Option B: stuck in Golgi. Unlikely, because that wouldn't prevent expression, just surface expression.

Option C: enhancer missing. Unlikely because the ligand is under a strong promoter.

Option D: not in frame. That would cause a nonfunctional protein, but the question is about lack of expression.

Wait, the question says that the Western blot after plasmid transfection shows a signal proportional to actin loading, which suggests the proteins are expressed. But that was in primary astrocytes, not in the mice. So in the mouse, maybe the expression is not happening because the stop cassette isn't removed.

So the correct reason is that the Cre can't recombine the lox2272 sites, so the stop cassette remains, preventing eGFP expression.

Wait, but the options don't directly state that. The options given are:

A) ligand and receptor are in a paracrine relationship.

B) the receptor-eGFP construct is stuck in the Golgi.

C) the enhancer for the ligand and receptor expression is missing.

D) the receptor and the eGFP are not in the frame.

Hmm, none of these directly address the issue with the lox sites not being recombined.

Wait, alternative approach: perhaps the vector is designed such that only one of the ORFs is expressed when Cre is present. The ligand is under CBA promoter, and the receptor is under IRES. But without Cre, the stop cassettes prevent expression of mCherry and eGFP. With Cre, the ligand's stop is removed, allowing mCherry, but the receptor's stop isn't removed, so eGFP isn't expressed.

But in this case, the mouse would express the ligand-mCherry and the receptor without eGFP. Wait, no, the receptor is fused to eGFP, so the stop cassette is after the receptor-eGFP. So if the stop isn't removed, the eGFP isn't expressed.

Wait, perhaps the IRES is not working, so the receptor isn't expressed. No, the IRES allows for internal initiation, so the receptor should be expressed after the ligand.

Alternatively, perhaps the vector is designed such that only the ligand is expressed, and the receptor isn't, but that would depend on the promoters.

Alternatively, perhaps the eGFP is not being expressed because the reading frame is wrong, which would be option D. But how would that happen? The stop cassette is between the receptor and eGFP. If the stop isn't removed, the eGFP isn't expressed. So the absence of eGFP is due to the stop cassette not being excised.

But how does that relate to the options? The options don't directly address the cre's inability to recombine the lox2272 sites.

Wait, another angle: perhaps the eGFP is under the same transcriptional unit as the receptor, but the stop cassette is in between. If the stop isn't excised, the eGFP isn't translated. So the problem is that the Cre isn't excising the lox2272 sites, leading to the eGFP not being expressed.

But in the options, the only one that touches on expression is C (enhancer missing) or D (out of frame). Alternatively, perhaps the lox sites are in the wrong orientation or the Cre isn't present. But the mouse is crossed with SOX10-Cre, so the Cre is present.

Wait, maybe the vector uses a different system. For example, loxP and lox2272 are designed to be recombined by different Cre variants, like loxP for standard Cre and lox2272 for a different Cre (like Cre-ER). If the question's Cre (SOX10-Cre) can't recombine lox2272 sites, then the eGFP stop cassette remains.

In that case, the eGFP isn't expressed because the Cre can't recombine the lox2272 sites, so the stop isn't removed.

Looking at the options, none directly address this. So perhaps the correct answer is option D: the receptor and eGFP are not in frame. Wait, but how would that relate to the lox sites?

Alternatively, perhaps the lox2272 sites are in a different reading frame, but that's probably not the case. Or perhaps the vector has a frame shift because the stop cassette is in a different frame, but I'm not sure.

Alternatively, perhaps the lox sites are in the wrong orientation. But the question doesn't mention anything about that.

Hmm, maybe I'm overcomplicating. Let's think about the expression.

The vector has two cassettes:

5' CBA promoter -> ligand ORF -> loxP stop loxP -> mCherry

IRES -> receptor ORF -> lox2272 stop lox2272 -> eGFP

In the absence of Cre, the stop cassettes prevent expression of mCherry and eGFP.

When Cre is present, it should excise the loxP and lox2272 sites, allowing mCherry and eGFP to be expressed.

If the Cre can't recombine the lox2272 sites, then the eGFP remains under the stop cassette and isn't expressed.

But the options don't state that. So perhaps the correct explanation is that the stop cassette wasn't removed because the Cre couldn't recombine the lox2272 sites, but that's not one of the options.

Looking at the options again, perhaps the enhancer is missing, but the ligand is under CBA, which has its own enhancers.

Wait, the problem says that the ligand is under the CBA promoter, and the receptor is after the IRES. So the IRES would drive the translation of the receptor independently of the promoter, but the transcription is driven by the same promoter as the ligand.

If the enhancer is missing, perhaps the ligand isn't expressed, but I think the ligand would still be expressed under the CBA promoter regardless of enhancers. So option C might not be the issue.

Alternatively, perhaps the IRES doesn't work, so the receptor isn't expressed, but that would mean no eGFP either. But the question is about eGFP not being expressed, not the receptor.

Wait, no, the receptor is fused to eGFP. So if the receptor isn't expressed, the eGFP wouldn't be either. But if the stop cassette isn't removed, the eGFP isn't expressed even if the receptor is.

Wait, but the IRES is after the ligand. So perhaps the ligand is expressed, then the IRES allows the receptor to be expressed in the same transcript. So the receptor is expressed, but then the stop cassette after eGFP prevents its expression unless excised.

So if the stop isn't excised, the eGFP isn't expressed, but the receptor's ORF is still expressed (without eGFP). But the question is about eGFP, which isn't present.

So the problem is that the stop cassette isn't excised, so eGFP isn't expressed.

Which brings me back to the issue of the Cre not being able to recombine the lox2272 sites.

But none of the options directly address that. So perhaps another angle: the construct is designed such that the eGFP is not in frame, so even if the stop is removed, it's not expressed correctly.

Wait, but the stop cassette is between the receptor and eGFP, so if the stop is removed, the eGFP should be expressed as a fusion with the receptor. Wait no, the receptor is fused to eGFP. So the stop is after the receptor-eGFP.

Wait, no, the vector setup is:

ligand ORF (with stop under loxP) fused to mCherry.

Then IRES, followed by receptor ORF, which is fused to eGFP, followed by a stop under lox2272.

So the structure is:

CBA promoter -> ligand ORF -> loxP-stop-loxP -> mCherry

IRES -> receptor ORF -> lox2272-stop-lox2272 -> eGFP.

Wait, no. The ligand ORF is at 5' end, fused to mCherry. The receptor is at 3' end, fused to eGFP. So the vector is:

5' CBA promoter -> ligand ORF -> loxP stop loxP -> mCherry

IRES -> receptor ORF -> lox2272 stop lox2272 -> eGFP

Wait, but IRES is between the ligand and receptor. So the transcript starts with the ligand, then the IRES allows the receptor to be translated. So the ligand and receptor are in the same transcript, but separate ORFs.

But the stop cassettes are between ligand and mCherry, and between receptor and eGFP.

So when Cre is present, the ligand's stop is removed, allowing mCherry to be expressed in frame with the ligand. Similarly, the receptor's stop is removed, allowing eGFP to be expressed in frame with the receptor.

Wait, no. The ligand is fused to mCherry. So the ORF is ligand-mCherry, with a stop in between. But the stop is flanked by loxP sites. So when Cre deletes the stop, the ligand and mCherry are in frame.

Similarly, the receptor is fused to eGFP, with a stop flanked by lox2272. So when Cre deletes the stop, the receptor and eGFP are in frame.

So if the stop isn't removed, the mCherry and eGFP aren't expressed.

But in the mouse, the Cre is SOX10-Cre. If the Cre can't recombine the lox2272 sites, then the eGFP isn't expressed.

So why can't the Cre recombine the lox2272 sites? Because standard Cre doesn't recognize them.

So the problem is that the Cre can't recombine the lox2272 stop cassette, so the eGFP isn't expressed. But how does that relate to the options?

The options don't directly address this. So perhaps the correct answer is option D: the receptor and eGFP are not in the frame. But that would mean that the reading frame is wrong, causing a frameshift. But the problem is that the stop isn't removed, so the eGFP isn't expressed at all.

Wait, but in this case, the stop cassette is between the receptor and eGFP. So the eGFP isn't being translated because the stop is in place. So it's not a frame issue, it's an expression issue.

Hmm, perhaps the IRES is not working, leading to the receptor not being expressed, but the question is about the eGFP not being expressed. I'm a bit stuck here.

Wait, perhaps the problem is that the IRES isn't allowing the receptor to be expressed, so the eGFP isn't either. But the IRES is supposed to drive the receptor's expression, regardless of the promoter, as it's a separate ORF.

Alternatively, perhaps the expression of the receptor is not happening, and thus the eGFP isn't either. But that would be a problem with the IRES or the promoter, which isn't one of the options.

Wait, another thought: perhaps the construct is designed such that the eGFP isn't in the same frame as the receptor. So when the stop cassette is removed, the eGFP is out of frame and not expressed. So even if the stop is removed, the eGFP isn't expressed because it's in a different frame.

Which would be option D: the receptor and eGFP are not in the frame. That would mean that after the stop is removed, the eGFP isn't in frame, leading to no expression.

But why would the eGFP be out of frame? Because the stop cassette is flanked by lox2272 sites, I think. If the stop is between the receptor and eGFP, but the reading frames are different, then upon removal, the eGFP might not be in frame. But the vector design should ensure that the eGFP is in frame with the receptor.

Wait, unless the stop cassette disrupts the frame. But the stop is between them, so when excised, the receptor and eGFP should be in frame.

Alternatively, perhaps the vector has the stop cassette in a way that disrupts the reading frame. But that would depend on the presence of the stop.

Hmm, I'm not entirely sure, but given the options, I think the most plausible answer is option D, that the receptor and eGFP are not in frame. But I'm not entirely confident.

Alternatively, perhaps the correct answer is option B: the receptor-eGFP is stuck in the Golgi. But I thought that would affect surface expression, not total expression. If the Western blot shows the protein, it would be present, but not at the surface. But the question's result is about eGFP not being visible under the microscope, which is consistent with the protein not being expressed.

So perhaps the correct reason is that the eGFP isn't being expressed because the stop cassette isn't removed, which is due to the Cre not being able to recombine the lox2272 sites. But since that's not an option, I'm forced to choose from the given options.

Wait, another angle: the vector might have the stop cassette for the receptor in the opposite orientation, so the Cre doesn't remove it, but that's not one of the options.

Alternatively, perhaps the eGFP is under the control of a promoter that isn't active, but the question says the eGFP is fused to the receptor.

Another thought: perhaps the vector is designed in a way that only one of the fluorescent proteins is expressed, but that's not the case here.

Wait, perhaps the IRES is not functional, so the receptor isn't expressed. But the problem states that the ligand is under the CBA promoter, which is strong, and the receptor is under the IRES. If the IRES isn't working, the receptor wouldn't be expressed, leading to no eGFP. But then why is the question about eGFP specifically? Also, the initial Western blot after transfection showed expression, so perhaps the IRES is working.

Putting it all together, I think the most likely reason is that the eGFP stop cassette wasn't excised because the Cre couldn't recombine the lox2272 sites, so the eGFP isn't expressed. However, since none of the options directly address this, I'll have to choose the best fit.

Looking again, option C says the enhancer is missing. If the enhancer is missing, the ligand and receptor wouldn't be expressed. But the ligand is under a strong promoter, so enhancer might not be critical. So perhaps option C isn't the issue.

So perhaps the correct answer is D: the receptor and eGFP are not in the frame. Alternatively, perhaps the issue is that the stop cassette isn't removed, but the options don't have that.

Wait, another possibility: the loxP and lox2272 are on the same chromosome, and the Cre isn't able to recombine them because they are in a different location. But I don't think that's relevant here.

Wait! The vector is a bicistronic vector, so the two ORFs are in the same transcript. The ligand and mCherry are in the same ORF, and the receptor and eGFP are in another. The stop cassettes are after each, so when Cre is present, they are removed, allowing the respective fluorescent proteins to be expressed.

If the Cre can't recombine the lox2272 sites, then the eGFP isn't expressed. But why would that be? Because the Cre doesn't recognize the lox2272 sites.

But in the options, the only thing that could explain that is option D, which suggests a frameshift, but I'm not sure.

Alternatively, perhaps the lox sites are in the wrong orientation. For example, if the lox2272 sites are in the same orientation, Cre can't recombine them, but I think the vector would have them in the correct orientation.

I'm getting stuck here. Let me think of what each option implies.

Option A: ligand and receptor are in a paracrine relationship. That would mean they act on neighboring cells, but that doesn't explain why eGFP isn't expressed.

Option B: receptor-eGFP stuck in Golgi. That would prevent surface expression but not total expression. Western blot would show it, but the fluorescence wouldn't if it's not on the surface. But the question's result is about the absence of eGFP, so perhaps this is possible.

Option C: enhancer missing. If the enhancer is missing, the ligand and receptor might not be expressed. But the ligand is under a strong promoter, so perhaps the receptor, which is after IRES, might not be expressed. But the question is about the eGFP, which is part of the receptor construct.

Option D: receptor and eGFP not in frame. So when the stop is removed, the eGFP is not expressed because it's in a different frame. But if the stop is removed correctly, the eGFP should be in frame.

Wait, another thought: perhaps the vector has the eGFP in a separate ORF, but the stop cassette is in the way. So without the stop being removed, the eGFP isn't expressed. But the Cre isn't able to remove it because of the lox site type.

But the options don't include that.

Given all this, I'm going to go with option D: the receptor and eGFP are not in the frame. Because if the stop isn't removed, the eGFP isn't expressed. But how does that relate to the frame? Maybe the stop cassette introduces a frameshift, causing the eGFP to be out of frame. So even if the stop is removed, the eGFP isn't in frame and isn't expressed.

Wait, but the stop cassette is between the receptor and eGFP. So the reading frame should be maintained. Unless the stop introduces a frameshift. But the stop is within the lox sites, which are probably in a different frame.

Alternatively, if the lox2272 site introduces a frameshift when not removed, but I'm not sure.

Alternatively, perhaps the vector has the eGFP in a different frame, making it impossible to express when the stop is removed. But that would be a design flaw, not an issue with the Cre.

I think I'm overcomplicating it. The most likely reason is that the Cre can't recombine the lox2272 sites, so the eGFP isn't expressed. But since that's not an option, I'll have to choose the best available option.

Wait, another possibility: perhaps the ligand is under the CBA promoter and the receptor is under the same promoter via the IRES. So the ligand is expressed, but the receptor isn't because the IRES isn't functional. But then the eGFP wouldn't be expressed either, but the question is about the eGFP, not the receptor.

Alternatively, perhaps the IRES is not compatible with the receptor, but I don't think that's one of the options.

Wait, perhaps the problem is that the eGFP is not being translated because the stop cassette isn't removed. So, the stop is still there, blocking eGFP expression.

But the options don't directly address this. So, perhaps the correct answer is option B: the receptor-eGFP is stuck in the Golgi, preventing surface expression, but the Western blot would still show the protein. Since the question states that the Western blot was done on total proteins and shows a signal proportional to actin, the eGFP is expressed but not on the surface. But then the fluorescent microscopy wouldn't see it, but that's not the case here.

Wait, but the result is that the eGFP isn't expressed at all. The Western blot after plasmid transfection (in astrocytes) shows a signal proportional to actin loading, which suggests the proteins are expressed. But in the mouse, the eGFP isn't expressed. So perhaps the issue is that the mouse construct isn't being expressed, possibly because the enhancer is missing.

Wait, option C says the enhancer is missing. If the enhancer is missing, the CBA promoter might not function properly in the mouse's cells, leading to no ligand and receptor expression. But the ligand is under the CBA, which is a strong constitutive promoter, so maybe the enhancer isn't needed. Hmm.

I'm getting more confused. I think I'll have to make an educated guess based on the options and the information.

The correct answer is likely option D: the receptor and eGFP are not in the frame. Because if the stop isn't removed, the eGFP isn't expressed. But the question is about why the eGFP isn't expressed, so the frame could be the issue.

Wait, no. The stop being present would prevent translation of eGFP. If the stop isn't removed, the eGFP isn't expressed. So the problem is that the stop isn't being cut, which is due to the Cre not being able to recombine the lox2272 sites.

But the options don't address this. So perhaps the correct answer is option B: the receptor-eGFP is stuck in the Golgi. But that would affect localization, not expression.

Wait, another angle: the vector is designed so that Cre deletes the stop only for the ligand, not the receptor. But that would require different lox sites for each.

So in this vector, the ligand's stop is flanked by loxP, and the receptor's by lox2272. So if the Cre can't recombine lox2272, the ligand's stop is removed, allowing mCherry, but the receptor's stop remains, so eGFP isn't expressed.

In that case, the reason would be that the Cre can't recombine lox2272 sites. But the options don't have this.

Given all that, I think the intended answer is option D: the receptor and eGFP are not in the frame. So I'll go with that.


The question involves a bicistronic vector expressing a ligand and receptor, with fluorescent markers (mCherry and eGFP) flanking stop cassettes under loxP and lox2272 sites, respectively. The ligand is under the CBA promoter, and the receptor is downstream of an IRES element. SOX10-Cre mice were used to recombine the lox sites, but no green signal (eGFP) was observed under confocal microscopy. The goal is to determine the most likely reason for this outcome.

### Key Analysis:
1. **Vector Design**:  
   - The ligand is at the 5' end, fused to mCherry, with a loxP-stop-loxP cassette preventing mCherry expression in the absence of Cre.  
   - The receptor is at the 3' end, fused to eGFP, with a lox2272-stop-lox2272 cassette preventing eGFP expression in the absence of Cre.  
   - SOX10-Cre is expected to recombine the lox sites, excising the stop cassettes and allowing expression of mCherry and eGFP.

2. **Observed Outcome**:  
   - No green signal (eGFP) was observed under confocal microscopy.  
   - A Western blot after plasmid transfection in astrocytes showed expression of the proteins, suggesting the constructs are functional but not expressed in the mouse model.

3. **Critical Issue**:  
   - The absence of eGFP suggests the stop cassette flanking eGFP was not excised.  
   - Lox2272 sites are not efficiently recombined by standard Cre, which may explain why the stop cassette remains intact, preventing eGFP expression.

4. **Option Analysis**:  
   - **(A) Ligand and receptor are in a paracrine relationship**: This describes their interaction but does not explain the lack of eGFP expression.  
   - **(B) The receptor-eGFP construct is stuck in the Golgi**: This would affect localization but not total expression. A Western blot would still detect the protein, but no such signal was observed.  
   - **(C) The enhancer for the ligand and receptor expression is missing**: The ligand is under the CBA promoter, which is strong and constitutive. The IRES element drives receptor expression post-translationally, so an enhancer is unlikely to be the issue.  
   - **(D) The receptor and eGFP are not in the frame**: If the stop cassette introduces a frameshift, eGFP would not be expressed even if the stop is removed. This aligns with the observed lack of eGFP expression.

### Conclusion:
The most plausible explanation is that the receptor and eGFP are not in the correct reading frame, preventing eGFP expression even if the stop cassette is removed. This aligns with the observed absence of fluorescence and the experimental setup.

ANSWER: D